Table 1 Some studies of checkpoint inhibitors before and after allo-HSCT.
Timing in relation to allo-HSCT | Drugs in use | Total number of cases | Disease | a-GVHD | c-GVHD | NRM | PFS/OS | Reference |
|---|---|---|---|---|---|---|---|---|
Pre- | Nivolumab | 39 | HL | 33% | 35% | 13% (1 year) | 69.4%/71.9%(1 year) | Martinez et al. [16] |
Pre- | Nivolumab | 9 | HL | 8/9 | 3/9 | 2/9 | −/− | Cheikh et al. [6] |
Pre- | Nivolumab | 15 | HL | 3/15 | 3/15 | 1/15 | −/− | Bekoz et al. [17] |
Pre- | Nivolumab | 209 | HL | 15% (180 days) Grade 3–4 | 34% | 14% (2 years) | 69%/82% (2 years) | Merryman et al. [14] |
Pre- | Nivolumab pembrolizumab | 24 | HL | 72% | 34.2% | 8.4% (10 months) | 63.7%/81.3% (1 year) | Ito et al. [18] |
Post- | Nivolumab | 20 | HL | – | 5/20 | 2/20 | −/− | Herbaux et al. [13] |
Post- | Nivolumab pembrolizumab | 31 | HL/NHL | 32% | 7% | 5/17 | −/− | Harvekos et al. [7] |
